Oana Danciu, MD, explained why phase 1 breast cancer trials are moving earlier in the treatment course and how disease stability guides patient selection.
|Videos|June 12, 2018
Can mRCC Patients Be Spared Debulking Nephrectomy?
Author(s)Daniel George, MD
In this video, Dr. Daniel George discusses CARMENA, which asked if cytoreductive surgery is necessary in the age of active systemic therapy for mRCC.
Advertisement
In this video, Dr. Daniel George discusses CARMENA, which asked if cytoreductive surgery is necessary in the age of active systemic therapy for mRCC.
Advertisement
Related to this article
ESMO Congress 2026 will feature updated findings on KRAS inhibitors, bispecific T-cell engagers, and other key modalities in the lung cancer field.
“What has changed is that we are bringing the phase 1 trials earlier in the course of treatment for our patients,” said Oana Danciu, MD.
Experts preview 6 breast cancer trials to watch at ESMO 2026, including KEYNOTE-B49, evERA, DESTINY-Breast11, SWITCH, PANKU-Breast01, and VIKTORIA-1.
An expert highlights OrigAMI-4, iza-bren plus pembrolizumab, GORTEC IDEAL, and HexAgon-HN ahead of the ESMO Congress 2026.
At the BIG10 CRC Summit, Mingjia Li, MD, outlined how pre-operative hemoglobin may signal treatment response in resectable NSCLC.
Experts highlight KEYNOTE-C93, TroFuse-005, and antibody-drug conjugate data in platinum-resistant ovarian cancer at the ESMO Congress 2026.
Nikolai Strusberg, MD, discussed other toxicities of proton vs photon breast RT, practice implications, and next steps in capsular contracture research.
Advertisement
Advertisement
Trending on CancerNetwork
1
Which Head and Neck Cancer Data Should You Watch For at ESMO 2026?
2
FDA Approves Pembrolizumab in Metastatic TMB-H Solid Tumors
3
Efficacy and Safety of Immune Checkpoint Inhibitors Combined With Chemoradiotherapy in Limited-Stage Small Cell Lung Cancer
4
Discussing Guidelines, New Data, and Earlier Referrals in Multiple Myeloma
5